You just read:

Janssen Pharmaceuticals, Inc. Announces Definitive Agreement to Divest U.S. License Rights to NUCYNTA® (tapentadol), NUCYNTA® ER (tapentadol) extended-release tablets and NUCYNTA® (tapentadol) Oral Solution

News provided by

Janssen Pharmaceuticals, Inc.

Jan 15, 2015, 04:05 ET